Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Anaptysbio Inc
(NQ:
ANAB
)
37.91
+0.16 (+0.42%)
Streaming Delayed Price
Updated: 9:40 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Anaptysbio Inc
< Previous
1
2
Next >
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
August 14, 2024
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
May 09, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 11, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
February 29, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
January 31, 2024
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
November 27, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Named a BioSpace 2024 Best Places to Work Winner
November 07, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Participation in November Investor Conferences
November 01, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
October 11, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
October 09, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
October 09, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
September 18, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
September 12, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
July 31, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces Participation in Upcoming Investor Conferences
May 30, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
May 11, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
May 02, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
April 06, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
March 27, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 01, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
February 27, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces Stock Repurchase Plan
January 13, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
January 05, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
December 02, 2022
From
AnaptysBio, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.